ForumIAS LATEST
- SFG FRC 2027 | Program starts from 15th Dec. 2026 | Admissions open for Tranche-1 Entrance Test till 25th Oct. 2026 Click Here to know more →
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 21st October onwards Click Here to Read More →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →
- The World Health Organisation (WHO) has recommended the use of the HIV drug dolutegravir(DTG) as the preferred first-line and second-line treatment for all populations.
- This drug can also be used for patients including pregnant women and those of childbearing potential.
- Dolutegravir(DTG) which is sold under the brand name Tivicay is an antiretroviral medication used together with other medication to treat HIV/AIDS.
- Studies have shown that DTG is more effective,easier to take and has fewer side effects than alternative drugs.It also has a high genetic barrier to developing drug resistance which is important given the rising trend of resistance.
- In 2019,82 low- and middle-income countries reported to be transitioning to DTG-based HIV treatment.The new recommendations aim at helping more nations improve their HIV policies.
- HIV stands for human immunodeficiency virus. It is the virus that can lead to acquired immunodeficiency syndrome (AIDS), if not treated. There are two main types of the virus: HIV-1 and HIV-2. HIV-2.
- At present there is no effective cure for HIV but HIV can be controlled. The medicine used to treat HIV is called antiretroviral therapy or ART.
